ORMP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ORMP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.
As of today, Oramed Pharmaceuticals's Future 3-5Y Total Revenue Growth Rate is N/A.
For the Biotechnology subindustry, Oramed Pharmaceuticals's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Oramed Pharmaceuticals's Future 3-5Y Total Revenue Growth Rate falls into.
Oramed Pharmaceuticals (NAS:ORMP) Future 3-5Y Total Revenue Growth Rate Explanation
Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.
In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.
Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Benjamin Shapiro | director | 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
Nadav Kidron | director, 10 percent owner | 142 W. 57TH ST., NEW YORK NY 10019 |
Yadin Rozov | director | 9 TERRACE CIRCLE, ARMONK NY 10504 |
Miriam Kidron | director | 2 ELZA STREET, JERUSALEM L3 93706 |
Michael Rabinowitz | officer: Chief Commercial Officer | 1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK NY 10036 |
Arie Mayer | director | MORAN 16, KFAR SABA L3 4428890 |
Netanel Derovan | officer: Chief Legal Officer | 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
David Silberman | officer: Chief Financial Officer | 20 MAMILLA AVENUE, JERUSALEM L3 9414904 |
Kevin Rakin | director | 36 CHURCH LANE, WESTPORT CT 06880 |
Michael Rabinowitz | officer: Chief Commercial Officer | MAXIM GROUP, LLC, 405 LEXINGTON AVENUE, NEW YORK NY 10174 |
Leonard Sank | director | 3 BLAIR ROAD, CAPE TOWN T3 8005 |
Gao Xiaoming | director | 11F. NO. 266 HANKOU ROAD, HUANGPU DISTRICT, SHANGHAI F4 2000001 |
Avraham Gabay | officer: CFO, Treasurer and Secretary | 2/4 HIGH-TECH PARK, P.O. BOX 39098, JERUSALEM L3 91390 |
Mark Daniel Hasleton | officer: VP Business Development | 13, HIBAT ZION, RAANANA, RAANANA L3 4338111 |
Aviad Friedman | director | HADASSA 6, TEL AVIV L3 6451306 |
From GuruFocus
By PRNewswire • 08-02-2023
By PRNewswire PRNewswire • 05-18-2023
By PRNewswire PRNewswire • 07-07-2022
By PRNewswire PRNewswire • 12-21-2022
By PRNewswire PRNewswire • 11-14-2022
By PRNewswire PRNewswire • 07-26-2022
By GuruFocus Research • 02-08-2024
By PRNewswire PRNewswire • 11-29-2022
By PRNewswire PRNewswire • 06-20-2023
By GuruFocus Research • 02-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.